Summit Global Investments Trims Stock Position in Gilead Sciences, Inc. $GILD

Summit Global Investments decreased its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 61.0% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 12,051 shares of the biopharmaceutical company’s stock after selling 18,810 shares during the period. Summit Global Investments’ holdings in Gilead Sciences were worth $1,680,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in GILD. Strategic Investment Solutions Inc. IL purchased a new stake in shares of Gilead Sciences during the 4th quarter valued at approximately $25,000. Vermillion & White Wealth Management Group LLC grew its position in Gilead Sciences by 71.4% in the fourth quarter. Vermillion & White Wealth Management Group LLC now owns 204 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 85 shares during the period. Quattro Advisors LLC purchased a new position in Gilead Sciences in the fourth quarter worth approximately $26,000. Wealth Preservation Advisors LLC increased its stake in Gilead Sciences by 60.0% during the fourth quarter. Wealth Preservation Advisors LLC now owns 216 shares of the biopharmaceutical company’s stock worth $27,000 after acquiring an additional 81 shares during the last quarter. Finally, Ares Financial Consulting LLC acquired a new stake in Gilead Sciences during the fourth quarter worth $28,000. Institutional investors and hedge funds own 83.67% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on GILD. Leerink Partners decreased their price target on Gilead Sciences from $148.00 to $146.00 in a research note on Friday, May 8th. Daiwa Securities Group reduced their price objective on shares of Gilead Sciences from $161.00 to $150.00 and set an “outperform” rating on the stock in a report on Tuesday, May 19th. Royal Bank Of Canada decreased their target price on shares of Gilead Sciences from $122.00 to $120.00 and set a “sector perform” rating on the stock in a research report on Tuesday, July 7th. Wall Street Zen raised shares of Gilead Sciences from a “hold” rating to a “buy” rating in a research note on Sunday, July 12th. Finally, The Goldman Sachs Group lifted their price target on shares of Gilead Sciences from $125.00 to $130.00 and gave the company a “neutral” rating in a research report on Friday, April 17th. Twenty-six analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $159.04.

Insider Activity at Gilead Sciences

In related news, CEO Daniel Patrick O’day sold 15,000 shares of Gilead Sciences stock in a transaction that occurred on Wednesday, July 1st. The shares were sold at an average price of $126.29, for a total value of $1,894,350.00. Following the completion of the transaction, the chief executive officer owned 607,133 shares in the company, valued at approximately $76,674,826.57. The trade was a 2.41% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew D. Dickinson sold 3,000 shares of the stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $125.40, for a total transaction of $376,200.00. Following the sale, the chief financial officer owned 171,646 shares in the company, valued at approximately $21,524,408.40. This trade represents a 1.72% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 77,000 shares of company stock worth $9,978,740. Corporate insiders own 0.30% of the company’s stock.

Gilead Sciences Trading Down 0.8%

Shares of NASDAQ GILD opened at $133.21 on Tuesday. The company has a current ratio of 1.97, a quick ratio of 1.77 and a debt-to-equity ratio of 0.89. The stock has a market capitalization of $165.39 billion, a PE ratio of 18.15 and a beta of 0.32. Gilead Sciences, Inc. has a twelve month low of $107.75 and a twelve month high of $157.29. The stock has a fifty day simple moving average of $129.72 and a 200-day simple moving average of $135.37.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.91 by $0.12. Gilead Sciences had a return on equity of 48.19% and a net margin of 30.99%.The firm had revenue of $6.96 billion for the quarter, compared to analyst estimates of $6.91 billion. During the same quarter in the prior year, the company earned $1.81 EPS. Gilead Sciences’s revenue was up 4.4% on a year-over-year basis. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. On average, equities analysts forecast that Gilead Sciences, Inc. will post -0.77 earnings per share for the current year.

Gilead Sciences Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Monday, June 29th. Stockholders of record on Monday, June 15th were paid a $0.82 dividend. The ex-dividend date of this dividend was Monday, June 15th. This represents a $3.28 annualized dividend and a dividend yield of 2.5%. Gilead Sciences’s dividend payout ratio (DPR) is presently 44.69%.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.